Xenon Pharmaceuticals Inc.
XENE
$37.51
-$0.68-1.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 50.87% | 38.31% | 44.79% | 32.86% | 12.86% |
| Gross Profit | -50.87% | -21.36% | -44.79% | -32.86% | -12.86% |
| SG&A Expenses | -0.81% | 28.71% | 42.68% | 30.47% | 67.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.36% | 35.90% | 44.29% | 32.31% | 24.23% |
| Operating Income | -36.36% | -23.20% | -44.29% | -32.31% | -24.23% |
| Income Before Tax | -46.48% | -35.99% | -54.70% | -29.81% | -22.18% |
| Income Tax Expenses | -87.99% | 3.64% | -1,777.07% | -103.82% | -51.36% |
| Earnings from Continuing Operations | -46.24% | -35.71% | -46.81% | -29.57% | -22.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.24% | -35.71% | -46.81% | -29.57% | -22.05% |
| EBIT | -36.36% | -23.20% | -44.29% | -32.31% | -24.23% |
| EBITDA | -36.71% | -23.31% | -45.42% | -35.32% | -24.43% |
| EPS Basic | -43.86% | -33.82% | -31.04% | -9.75% | -3.50% |
| Normalized Basic EPS | -44.09% | -34.09% | -37.64% | -8.86% | -1.41% |
| EPS Diluted | -43.86% | -33.82% | -31.04% | -9.75% | -3.50% |
| Normalized Diluted EPS | -44.09% | -34.09% | -37.64% | -8.86% | -1.41% |
| Average Basic Shares Outstanding | 1.65% | 1.41% | 12.03% | 18.07% | 17.93% |
| Average Diluted Shares Outstanding | 1.65% | 1.41% | 12.03% | 18.07% | 17.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |